Home » Research
TRANSLATIONAL RESEARCH SHARED RESOURCE
Director:Hallgeir Rui, MD, PhD |
|
Histology Section Location:308 BLSB |
Histology Section Contact:
Zhijiu Zhong, MD, MS
|
AQUA Core Location:330 BLSB |
AQUA Core Contact:
Melanie Girondo |
This Facility provides the KCC with five core functions:
- Tissue procurement, banking, and distribution
- Tissue processing and Histology services; frozen and fixed tissues
- Microdissection of tissues and laser capture of individual cells
- Immunohistochemical staining of tissue sections
- Quality assurance and clinical-pathologic data collection.
Note: (all protocols must have IRB approval before requesting tissues)
Frozen and paraffin embedded tissues are available to participating scientists either from the tissue bank, or from paraffin block archives. Basic histologic services include processing, slide preparation and staining of human and animal tissues. Immunohistochemical staining is performed on paraffin sections, frozen tissue or cytologic preparations, utilizing a broad range of commercial antibodies or reagents provided by the investigator. Specimens requiring microdissection or laser capture of individual cell types are processed via microscopic evaluation by the Core surgical pathologists. All specimens are reviewed as to organ type, tumor content, and tissue viability. Where appropriate and IRB approved, clinical-pathologic data can be requested.
Links to request forms for most Facility services are provided above and can be downloaded and filled out. Requests for archived blocks should go to 285 Main; tissue requests should be discussed with Dr. McCue (5-5588), or a collaborating pathologist so that the archive search can be scheduled.
Immunohistochemistry requests for standard antisera should go to Rm. 308 BLSB, as should all histology requests (processing of tissues, embedding, sections, H&E, other stains). Histology and Immunohistochemistry request forms with relevant tissues or blocks should be delivered to Rm. 308 BLSB, X3-3858.
Microdissection requests and requests for Pathology review of sections and slides should be made to individual collaborating surgical pathologists. Laser Microdissection requests should be discussed with Mark Curtis.
Questions about Facility use and services? Contact Zhihiu Zhong (3-3858/3-1808), Melanie Girondo (3-9257), Hallgeir Rui (5-9259) or Peter McCue (5-5588).
TRANSLATIONAL RESEARCH CORE FACILITY PERSONNEL
Histology/Immunohistochemistry
|
|
Biorepository
Peter A. McCue, M.D., Director of Surgical Pathology
Phone: 5-5588, 285 D Main Building
Email: Peter.McCue@jefferson.edu
Laser Capture Microdissection
Mark Curtis, M.D., Surgical Pathology
Phone: 5-4404, Room 285 Main Building
Email: Mark Curtis@Jefferson.edu
Oversight Committee
Hallgeir Rui, Peter McCue,Andrew Quong, Richard Davidson, Andrew Aplin, Louise Fong
Selected publications:
1. Arafat H, Lazar M, Salem K, Chipitsyna G, Gong Q, Pan TC, Zhang RZ, Yeo CJ, Chu ML. Tumor-specific expression and alternative splicing of the COL6A3 gene in pancreatic cancer. Surgery. 2011 Aug;150(2):306-15.
2. Arendt LM, Evans E, Rugowski D, Garcia-Barchino MJ, Rui H, Schuler LA. Ovarian Hormones Are Not Required for PRL-induced Mammary Tumorigenesis, But Estrogen Enhances Neoplastic Processes, Journal of Endocrinology, 203, 99-110, 2009.
3. Arendt LM, Rugowski DE, Grafwallner-Huseth TA, Garcia Barchino MJ, Rui H, Schuler LA. Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer. Breast Cancer Research, 13:R11, 2011 (15 pages).
4. Balliet RM, Capparelli C, Guido C, Pestell TG, Martinez-Outschoorn UE, Lin Z, Whitaker-Menezes D, Chiavarina B, Pestell RG, Howell A, Sotgia F, Lisanti MP. Mitochondrial oxidative stress in cancer-associated fibroblasts drives lactate production, promoting breast cancer tumor growth: understanding the aging and cancer connection. Cell Cycle. 2011 Dec 1;10(23):4065-73.
5. Behling C, Tang A, Freydin B, Chervoneva I, Sameep K, Schwartz GF, Rui H, Witkiewicz AK. Increased SIAH expression predicts ductal carcinoma in situ (DCIS) progression to invasive carcinoma. Breast Cancer Res Treat. 129, 717-24, 2011.
6. Bryant KG, Camacho J, Jasmin JF, Wang C, Addya S, Casimiro MC, Fortina P, Balasubramaniam S, Knudsen KE, Schwarting R, Lisanti MP, Mercier I. Caveolin-1 overexpression enhances androgen-dependent growth and proliferation in the mouse prostate. Int J Biochem Cell Biol. 2011 Sep;43(9):1318-29.
7. Capozza F, Trimmer C, Castello-Cros R, Katiyar S, Whitaker-Menezes D, Follenzi A, Crosariol M, Llaverias G, Sotgia F, Pestell RG, Lisanti MP. Genetic ablation of Cav1 differentially affects melanoma tumor growth and metastasis in mice. Role of Cav1 in Shh heterotypic signaling and transendothelial migration. Cancer Res. 2012 Mar 6. [Epub ahead of print]
8. Castello-Cros R, Bonuccelli G, Molchansky A, Capozza F, Witkiewicz AK, Birbe RC, Howell A, Pestell RG, Whitaker-Menezes D, Sotgia F, Lisanti MP. Matrix remodeling stimulates stromal autophagy, "fueling" cancer cell mitochondrial metabolism and metastasis. Cell Cycle. 2011 Jun 15;10(12):2021-34.
9. Castello-Cros R, Whitaker-Menezes D, Molchansky A, Purkins G, Soslowsky LJ, Beason DP, Sotgia F, Iozzo RV, Lisanti MP. Scleroderma-like properties of skin from caveolin-1-deficient mice: implications for new treatment strategies in patients with fibrosis and systemic sclerosis. Cell Cycle. 2011 Jul 1;10(13):2140-50.
10. Castorino JJ, Gallagher-Colombo SM, Levin AV, Fitzgerald PG, Polishook J, Kloeckener-Gruissem B, Ostertag E, Philp NJ. Juvenile cataract-associated mutation of solute carrier SLC16A12 impairs trafficking of the protein to the plasma membrane. Invest Ophthalmol Vis Sci. 2011 Aug 29;52(9):6774-84.
11. Chiavarina B, Whitaker-Menezes D, Martinez-Outschoorn UE, Witkiewicz AK, Birbe RC, Howell A, Pestell RG, Smith J, Daniel R, Sotgia F, Lisanti MP. Pyruvate kinase expression (PKM1 and PKM2) in cancer-associated fibroblasts drives stromal nutrient production and tumor growth. Cancer Biol Ther. 2011 Dec 15;12(12). [Epub ahead of print]
12. Comstock CES, Augello MA, Benito RP, Karch J, Tran TH, Utama FE, Tindall E, Wang Y, Burd CJ, Groh EM, Hoang HN, Giles GG, Severi G, Hayes VM, Henderson BE, Le Marchand L, Kolonel LN, Haiman CA, Baffa R, Gomella LG, Knudsen ES, Rui H, Henshall SM, Sutherland RL and Knudsen KE. Cyclin D1 splice variants: polymorphism, risk, and isoform specific regulation in prostate cancer. Clinical Cancer Research, 15, 5338-49, 2009.
13. Crist RC, Roth JJ, Waldman SA, Buchberg AM. A conserved tissue-specific homeodomain-less isoform of MEIS1 is downregulated in colorectal cancer. PLoS One. 2011;6(8):e23665.
14. Dagvadorj A, Tan S, Xie J, Nurmi M, Alanen K, Rui H, Mirtti T, Nevalainen MT. N-Terminal truncation of Stat5a/b circumvents PIAS3-mediated inhibition of Stat5 in prostate cancer cells. Int J Biochem Cell Biol, 42, 2037-46, 2010.
15. Dalmizrak O, Wu A, Chen J, Sun H, Utama FE, Zambelli D, Tran TH, Rui H, Baserga R. The insulin receptor substrate-1 regulates the transformed phenotype of BT-20 human breast cancer cells. Cancer Research, 67, 2124-30, 2007.
16. de Almeida CJ, Witkiewicz AK, Jasmin JF, Tanowitz HB, Sotgia F, Frank PG, Lisanti MP. Caveolin-2-deficient mice show increased sensitivity to endotoxemia. Cell Cycle. 2011 Jul 1;10(13):2151-61.
17. Dickinson GS, Alugupalli KR. Deciphering the role of Toll-like receptors in humoral responses to Borreliae. Front Biosci (Schol Ed). 2012 Jan 1;4:699-712.
18. Ertel A, Dean JL, Rui H, Liu C, Witkiewicz AK, Knudsen KE, Knudsen ES. RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. Cell Cycle, 9, 4153-63, 2010.
19. Gormley M, Minkeu A, Meng R, Zhong Z, Quong AA. Proteomic profiling of infiltrating ductal carcinoma reveals increased cellular interactions with tissue microenvironment. J Proteome Res. 2012 Feb 22. [Epub ahead of print]
20. HuangFu WC, Qian J, Liu C, Liu J, Barker D, Lokshin A, Rui H, Fuchs S. Inflammatory signaling compromises cell responses to interferon alpha. Oncogene, 23,838-40, 2011.
21. HuangFu W-C, Qian J, Liu C, Rui H, Fuchs SY. Melanoma cell-secreted soluble factor that stimulates ubiquitination and degradation of the interferon alpha receptor and attenuates its signaling. Pigment Cell & Melanoma Research, 23; 838-40, 2010.
22. Jensen DA, Steplewski A, Gawron K, Fertala A. Persistence of intracellular and extracellular changes after incompletely suppressing expression of the R789C (p.R989C) and R992C (p.R1192C) collagen II mutants. Hum Mutat. 2011 Jul;32(7):794-805.
23. Johnson KJ, Peck AR, Liu C, Tran TH, Utama FE, Sjolund AB, Schaber JD, Witkiewicz AK, Rui H. PTP1B suppresses prolactin activation of Stat5 in breast cancer cells. Am J Pathol, 177, 2971-2983, 2010.
24. Katiyar S, Jiao X, Addya S, Ertel A, Covarrubias Y, Rose V, Casimiro MC, Zhou J, Lisanti MP, Nasim T, Fortina P, Pestell RG. Mammary Gland Selective Excision of c-Jun Identifies Its Role in mRNA Splicing. Cancer Res. 2012 Feb 15;72(4):1023-34.
25. Kerkelä R, Boucher M, Zaka R, Gao E, Harris D, Piuhola J, Song J, Serpi R, Woulfe KC, Cheung JY, O'Leary E, Bonventre JV, Force T. Cytosolic phospholipase A(2)? protects against ischemia/reperfusion injury in the heart. Clin Transl Sci. 2011 Aug;4(4):236-42.
26. Knudsen ES, Ertel A, Davicioni E, Kline J, Schwartz GF, Witkiewicz AK. Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia. Breast Cancer Res Treat. 2011 Dec 2. [Epub ahead of print]
27. Lal H, Zhou J, Ahmad F, Zaka R, Vagnozzi RJ, Decaul M, Woodgett J, Gao E, Force T. Glycogen synthase kinase-3? limits ischemic injury, cardiac rupture, post-myocardial infarction remodeling and death. Circulation. 2012 Jan 3;125(1):65-75.
28. Lebaron, MJ, Ahonen, TJ, Nevalainen, MT, and Rui, H. In vivo response-based identification of direct hormone target cell populations using high-density tissue arrays. Endocrinology, 48, 989-1008, 2007.
29. Li D, Zhao Y, Liu C, Chen X, Qi Y, Jiang Y, Zou C, Zhang X, Liu S, Wang X, Zhao D, Sun Q, Zeng Z, Dress A, Lin MC, Kung HF, Rui H, Liu LZ, Mao F, Jiang BH, Lai L. Analysis of miR-195 and miR-497 expression, regulation and role in breast cancer. Clinical Cancer Research, 17, 1722-30, 2011.
30. Lin JE, Snook AE, Li P, Stoecker BA, Kim GW, Magee MS, Garcia AV, Valentino MA, Hyslop T, Schulz S, Waldman SA. GUCY2C Opposes Systemic Genotoxic Tumorigenesis by Regulating AKT-Dependent Intestinal Barrier Integrity. PLoS One. 2012;7(2):e31686.
31. Lindsay J, Jiao X, Sakamaki T, Casimiro MC, Shirley LA, Tran TH , Ju X, Liu M, Li Z, Wang C, Katiyar S, Rao M, Allen KG, Glazer RI, Ge C, Stanley P, Lisanti MP, Rui H and Pestell RG. ErbB2 induces Notch1 activity and function in breast cancer cells. Clinical and Translational Science, 1, 107-115, 2008.
32. Martinez-Outschoorn UE, Whitaker-Menezes D, Lin Z, Flomenberg N, Howell A, Pestell RG, Lisanti MP, Sotgia F. Cytokine production and inflammation drive autophagy in the tumor microenvironment: role of stromal caveolin-1 as a key regulator. Cell Cycle. 2011 Jun 1;10(11):1784-93.
33. McClendon AK, Dean JL, Ertel A, Fu Z, Rivadeneira DB, Reed CA, Bourgo RJ, Witkiewicz A, Addya S, Mayhew CN, Grimes HL, Fortina P, Knudsen ES. RB and p53 cooperate to prevent liver tumorigenesis in response to tissue damage. Gastroenterology. 2011 Oct;141(4):1439-50.
34. McGhee A, Sivarajah M, Gong Q, Lim S, Chipitsyna G, Yeo CJ, Arafat HA. Angiotensin II type 2 receptor blockade inhibits fatty acid synthase production through activation of AMP-activated protein kinase in pancreatic cancer cells. Surgery. 2011 Aug;150(2):284-98.
35. Mercier I, Casimiro MC, Zhou J, Wang C, Plymire C, Bryant KG, Daumer KM, Sotgia F, Bonuccelli G, Witkiewicz AK, Lin J, Tran TH, Milliman J, Frank PG, Jasmin J-F, Rui H, Pestell RG, Lisanti MP. Genetic Ablation of Caveolin-1 Drives Estrogen-Hypersensitivity and the Development of DCIS-like Mammary Lesions. The American Journal of Pathology, 174, 1172-90, 2009.
36. Michal A, Tran TH, Peck AR, Liu C, Rimm DL, Rui H, Benovic JL. Differential expression of arrestins is a predictor of breast cancer progression and survival. Breast Cancer Research and Treatment, 130, 791-807, 2011.
37. Millar EKA, Dean JL, Catriona M, McNeil CM, O'Toole SA, Henshall SM, Tran TH, Lin J, Witkiewicz A, Musgrove EA, Rui H, Haiman C, Knudsen KE, Robert L. Sutherland RL, Knudsen ES. Cyclin D1b protein is an independent marker of poor prognosis in breast cancer, Cancer Research, 28, 1812-20, 2009.
38. Neilson LM, Zhu J, Xie J, Malabarba MG, Sakamoto K, Wagner K-U, Kirken RA, Rui H. Coactivation of Jak1 Positively Modulates Prolactin-Jak2 Signaling in Breast Cancer: Recruitment of ERK and Stat3 and Enhancement of Akt and Stat5a/b Pathways. Mol Endo, 21, 2218-2232, 2007.
39. Peck AR, Witkiewicz AK, Liu C, Stringer GA, Klimowicz AC, Pequignot E, Freydin B, Tran TH, Yang N, Rosenberg AL, Hooke JA, Kovatich AJ, Nevalainen MT, Shriver CD, Hyslop T, Sauter G, Rimm DL, Magliocco AM, Rui H. Loss of Nuclear Localized and Tyrosine Phosphorylated Stat5 in Breast Cancer Predicts Poor Clinical Outcome and Increased Risk of Anti-Estrogen Therapy Failure. J Clin Oncol, 18, 2448-53, 2011. Subject of Editorial: Tweardy D, Chang JC. Stat5: from breast development to cancer prognosis, prediction, and progression. J Clin Oncol. 29, 2443-4, 2011.
40. Plotnikov A, Li Y, Tran TH, Tang W, Palazzo JP, Rui H, and Fuchs SY. Oncogene-mediated inhibition of glycogen synthase kinase 3? impairs degradation of prolactin receptor. Cancer Research, Cancer Research, 68, 354-61, 2008.
41. Plotnikov A, Varghese B, Tran TH, Rui H, and Fuchs SY. Impaired turnover of prolactin receptor contributes to transformation of human breast cells. Cancer Research, 69, 3165-72, 2009.
42. Ponnappan RK, Markova DZ, Antonio PJ, Murray HB, Vaccaro AR, Shapiro IM, Anderson DG, Albert TJ, Risbud MV. An organ culture system to model early degenerative changes of the intervertebral disc. Arthritis Res Ther. 2011 Oct 21;13(5):R171. [Epub ahead of print]
43. Popov VM, Zhou J, Shirley LA, Wu K, Vadlamudi RK, Kumar R, Jiang J, Quong J, Rui H, Yeow W-S, Wang C, and Pestell RG. The Cell Fate Determination Factor DACH1 is expressed in Estrogen Receptor ? (ER?) positive breast cancer and represses ER? signaling. Cancer Research, 69, 5752-60, 2009.
44. Richards NG, Rittenhouse DW, Freydin B, Cozzitorto JA, Grenda D, Rui H, Gonye G, Kennedy EP, Yeo CJ, Brody JR, Witkiewicz AK. HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients. Annals of Surgery, 252, 499-505, discussion 505-506, 2010.
45. Salem AF, Bonuccelli G, Bevilacqua G, Arafat H, Pestell RG, Sotgia F, Lisanti MP. Caveolin-1 promotes pancreatic cancer cell differentiation and restores membranous E-cadherin via suppression of the epithelial-mesenchymal transition. Cell Cycle. 2011 Nov 1;10(21):3692-700.
46. Sato T, Neilson LM, Peck AR, Liu C, Tran TH, Witkiewicz A, Hyslop T, Nevalainen MT, Sauter G, and Rui H. Signal transducer and activator of transcription-3 and breast cancer prognosis. American Journal of Cancer Research 1:347-355, 2011.
47. Shah S, Prasad S, Knudsen KE. Targeting pioneering factor and hormone receptor cooperative pathways to suppress tumor progression. Cancer Res. 2012 Mar 1;72(5):1248-59.
48. Snook AE, Magee MS, Marszalowicz GP, Schulz S, Waldman SA. Epitope-targeted cytotoxic T cells mediate lineage-specific antitumor efficacy induced by the cancer mucosa antigen GUCY2C. Cancer Immunol Immunother. 2011 Nov 6. [Epub ahead of print]
49. Sotgia F, Casimiro MC, Bonuccelli G, Liu M, Whitaker-Menezes D, Er O, Daumer KM, Mercier I, Witkiewicz AK, Minetti C, Capozza F, Gormley M, Quong AA, Rui H, Frank PG, Milliman JN, Knudsen ES, Zhou J, Wang C, Pestell RG, Lisanti MP. Loss of Caveolin-3 Induces a Lactogenic Microenvironment that is Protective Against Mammary Tumor Formation. American Journal of Pathology, 174,613-629, 2009.
50. Sotgia F, Whitaker-Menezes D, Martinez-Outschoorn UE, Flomenberg N, Birbe RC, Witkiewicz AK, Howell A, Philp NJ, Pestell RG, Lisanti MP. Mitochondrial metabolism in cancer metastasis: Visualizing tumor cell mitochondria and the "Reverse Warburg Effect" in positive lymph node tissue. Cell Cycle. 2012 Apr 1;11(7). [Epub ahead of print]
51. Steplewski A, Kasinskas A, Fertala A. Remodeling of the dermal-epidermal junction in bilayered skin constructs after silencing the expression of the p.R2622Q and p.G2623C collagen VII mutants. Connect Tissue Res. 2012 Feb 21. [Epub ahead of print]
52. Stolla M, Stefanini L, André P, Ouellette TD, Reilly MP, McKenzie SE, Bergmeier W. CalDAG-GEFI deficiency protects mice in a novel model of Fc? RIIA-mediated thrombosis and thrombocytopenia. Blood. 2011 Jul 28;118(4):1113-20.
53. Sullivan J, Blair L, Alnajar A, Aziz T, Chipitsyna G, Gong Q, Yeo CJ, Arafat HA. Expression and regulation of nicotine receptor and osteopontin isoforms in human pancreatic ductal adenocarcinoma. Histol Histopathol. 2011 Jul;26(7):893-904.
54. Tran CM, Smith HE, Symes A, Rittié L, Perbal B, Shapiro IM, Risbud MV. Transforming growth factor ? controls CCN3 expression in nucleus pulposus cells of the intervertebral disc. Arthritis Rheum. 2011 Oct;63(10):3022-31.
55. Tran TH, Utama FE, Lin J, Yang N, Sjolund AB, Ryder A, Johnson KJ, Neilson LM, Liu C, Brill KL, Rosenberg AL, Witkiewicz AK, Rui H. Prolactin Inhibits Expression of the Proto-oncogene BCL6 in Breast Cancer through a Stat5 Dependent Mechanism. Cancer Research, 70, 1711-21, 2010.
56. Utama, FE, Tran TH, Ryder A, LeBaron MJ, Parlow AF, Rui H. Insensitivity of human prolactin receptors to non-human prolactins: Relevance for experimental modeling of prolactin receptor-expressing human cells. Endocrinology, 150, 1782-90, 2009.
57. Valentino MA, Lin JE, Snook AE, Li P, Kim GW, Marszalowicz G, Magee MS, Hyslop T, Schulz S, Waldman SA. A uroguanylin-GUCY2C endocrine axis regulates feeding in mice. J Clin Invest. 2011 Sep;121(9):3578-88.
58. Varghese B, Swaminathan G, Plotnikov A, Tzimas C, Yang N, Rui H, Fuchs SY. Prolactin inhibits activity of pyruvate kinase M2 to stimulate cell proliferation. Mol Endo 24; 2356-65, 2010.
59. Wang J, Markova D, Anderson DG, Zheng Z, Shapiro IM, Risbud MV. TNF-α and IL-1β promote a disintegrin-like and metalloprotease with thrombospondin type I motif-5-mediated aggrecan degradation through syndecan-4 in intervertebral disc. J Biol Chem. 2011 Nov 18;286(46):39738-49.
60. Wang Y, Dean JL, Millar EK, Tran TH, McNeil CM, Burd CJ, Henshall SM, Utama FE, Witkiewicz A, Rui H, Sutherland RL, Knudsen KE, Knudsen ES. Cyclin D1b Is Aberrantly Regulated in Response to Therapeutic Challenge and Promotes Resistance to Estrogen Antagonists, Cancer Research 68, 5628-5638, 2008.
61. Wei G, Wang M, Hyslop T, Wang Z, Carr BI. Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo. Int J Cancer. 2010 Dec 15;127(12):2949-58.
62. Whitaker-Menezes D, Martinez-Outschoorn UE, Flomenberg N, Birbe RC, Witkiewicz AK, Howell A, Pavlides S, Tsirigos A, Ertel A, Pestell RG, Broda P, Minetti C, Lisanti MP, Sotgia F. Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue. Cell Cycle. 2011 Dec 1;10(23):4047-64.
63. Witkiewicz AK, Dasgupta A, Nguyen KH, Liu C, Kovatich AJ, Schwartz GF, Pestell RG, Sotgia F, Rui H, Lisanti MP. Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer. Cancer Biology & Therapy, 8, 1-9, 2009.
64. Witkiewicz AK, Freydin B, Chervoneva I, Potoczek M, Rizzo W, Rui H, Brody JR, Schwartz GF, Lisanti MP. Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrence. Cancer Biol Ther, 10; 391-6, 2010.
65. Witkiewicz AK, Rivadeneira DB, Ertel A, Kline J, Hyslop T, Schwartz GF, Fortina P, Knudsen ES. Association of RB/p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironment. Am J Pathol. 2011 Sep;179(3):1171-8.
66. Witkiewicz AK, Whitaker-Menezes D, Dasgupta A, Philp NJ, Lin Z, Gandara R, Sneddon S, Martinez-Outschoorn UE, Sotgia F, Lisanti MP. Using the "reverse Warburg effect" to identify high-risk breast cancer patients: Stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers. Cell Cycle. 2012 Mar 15;11(6). [Epub ahead of print]
67. Wu KN, Queenan M, Brody JR, Potoczek M, Sotgia F, Lisanti MP, Witkiewicz AK. Loss of stromal caveolin-1 expression in malignant melanoma metastases predicts poor survival. Cell Cycle. 2011 Dec 15;10(24):4250-5.
68. Zhang H, Zhou X, McQuade T, Li J, Chan FK, Zhang J. Functional complementation between FADD and RIP1 in embryos and lymphocytes. Nature. 2011 Mar 17;471(7338):373-6.
69. Zhang Q, Sakamoto K, Liu C, Triplett AA, Lin W, Rui H, Wagner K-U. Cyclin D3 compensates for the loss of Cyclin D1 during ErbB2-induced mammary tumor initiation and progression. Cancer Research, 71,7513-24, 2011.
Maintained by the Informatics Shared Resources at the Kimmel Cancer Center at Jefferson
Copyright© Thomas Jefferson University. All Rights Reserved.
The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement